EGFR and non-small cell lung carcinoma: Previous studies (84) have shown that PD-L1 expression is also increased in NSCLC patients after developing resistance to EGFR-TKIs, and RELB may up-regulate PD-L1 expression following EGFR-TKIs resistance in NSCLC.